Search

Search Results

• 

  Acne exacerbation after tofacitinib treatment for alopecia areata

  Sawsan Alharthi, Mohammed G. Turkmani, Mohammed I. AlJasser

  01-01-2022

  https://doi.org/10.4081/dr.2022.9396

  2606

  PDF: 864

  HTML: 31
• 

  Atopic dermatitis: a brief review of recent advances in its management

  Sultan Daghafak Alenazi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9678

  2394

  PDF: 1409

  HTML: 106

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2690

  PDF: 982

  HTML: 31

• Rosacea-like eruptions associated with upadacitinib in atopic dermatitis: two case reports and management strategies

  Claudia Paganini, Edoardo Mortato, Lorenzo Tofani, Alfredo Belcastro, Marina Talamonti, Cosimo Di Raimondo, Luca Bianchi, Marco Galluzzo

  04-03-2025

  https://doi.org/10.4081/dr.2025.10193

  747

  PDF: 531

  HTML: 4
• 

  Vitiligo: What’s old, what’s new

  Mariabeatrice Bertolani, Eleonora Rodighiero, Maria Beatrice de Felici del Giudice, Torello Lotti, Claudio Feliciani, Francesca Satolli

  15-09-2021

  https://doi.org/10.4081/dr.2021.9142

  2658

  PDF: 1145

  HTML: 207

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  406

  PDF: 273

  HTML: 11

• Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review

  Atheer G. Almutairi, Abeer G. Almutairi, Rahaf R. Almutairi, Asem Shadid, Alhanouf A. Bin Dakhil, Lamia Alakrash

  29-01-2025

  https://doi.org/10.4081/dr.2025.10257

  635

  PDF: 369

  SUPPLEMENTARY MATERIAL: 49

  HTML: 5

• Severe relapse of generalized psoriasis in a young patient with a Löfgren syndrome history

  Ermira Ziçishti, Migena Vargu, Sabina Dedej, Eriselda Kurushi, Valbona Zenelaj, Ermira Vasili

  13-03-2025

  https://doi.org/10.4081/dr.2025.10021

  442

  PDF: 305

  HTML: 7
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1686

  PDF: 679

  HTML: 85

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  540

  PDF: 306

• Psoriasiform eruption induced by dupilumab successfully treated with upadacitinib

  Mattia Minghini, Natale Schettini, Lucrezia Pacetti, Chiara Bocchi, Alessandro Borghi

  16-10-2025

  https://doi.org/10.4081/dr.2025.10588

  254

  PDF: 154

• Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient Use of upadacitinib in pediatric comorbidities

  Edoardo Mortato, Ludovico Maria Rao, Marina Aloi, Arnaldo Cioni, Enrico Matteini, Angela Fico, Sara Lambiase, Ruslana Gaeta Shumak, Luca Bianchi, Elena Campione, Laura Diluvio

  09-01-2026

  https://doi.org/10.4081/dr.2026.10165

  615

  PDF: 341

• Successful treatment of refractory generalized granuloma annulare with abrocitinib

  Caterina Mariarosaria Giorgio, Anna Balato, Gaetano Licata, Vittorio Tancredi, Giuseppe Argenziano, Eugenia Veronica Di Brizzi

  23-01-2026

  https://doi.org/10.4081/dr.2026.10296

  364

  PDF: 185

• Successful use of upadacitinib for the improvement of vitiligo-like and perifollicular dyspigmentation (salt-and-pepper skin) in systemic sclerosis

  Giovanni Paolino, Matteo Riccardo Di Nicola, Santo Raffaele Mercuri, Valentina Canti

  12-02-2026

  https://doi.org/10.4081/dr.2026.10652

  272

  PDF: 169